[go: up one dir, main page]

AR043968A1 - Oxido nitrico en el tratamiento de inflamacion - Google Patents

Oxido nitrico en el tratamiento de inflamacion

Info

Publication number
AR043968A1
AR043968A1 ARP040101134A ARP040101134A AR043968A1 AR 043968 A1 AR043968 A1 AR 043968A1 AR P040101134 A ARP040101134 A AR P040101134A AR P040101134 A ARP040101134 A AR P040101134A AR 043968 A1 AR043968 A1 AR 043968A1
Authority
AR
Argentina
Prior art keywords
nitric oxide
inflammation
treatment
inflammation treatment
medicament
Prior art date
Application number
ARP040101134A
Other languages
English (en)
Original Assignee
Aga Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aga Ab filed Critical Aga Ab
Publication of AR043968A1 publication Critical patent/AR043968A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de óxido nítrico, en la forma de óxido nítrico gaseoso o un dador de óxido nítrico, en combinación con un glucocorticoide para fabricación de un medicamento para tratar la inflamación infecciosa en un mamífero, incluyendo el ser humano, dicha combinación se utiliza en una cantidad terapéuticamente eficaz para lograr el tratamiento de dicha inflamación. Métodos y una composición farmacéutica para el tratamiento de tal inflamación. Uso de óxido nítrico, en la forma de óxido nítrico gaseoso o un dador de óxido nítrico, para la fabricación de un medicamento para aumentar la expresión del receptor de glucocorticoides en la célula de un mamífero, incluyendo el ser humano. Un método para tal aumento.
ARP040101134A 2003-04-03 2004-04-02 Oxido nitrico en el tratamiento de inflamacion AR043968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0300971A SE0300971D0 (sv) 2003-04-03 2003-04-03 Nitric oxide in treatment of inflammation

Publications (1)

Publication Number Publication Date
AR043968A1 true AR043968A1 (es) 2005-08-17

Family

ID=20290910

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101134A AR043968A1 (es) 2003-04-03 2004-04-02 Oxido nitrico en el tratamiento de inflamacion

Country Status (11)

Country Link
US (2) US20050069595A1 (es)
EP (1) EP1608405A2 (es)
JP (1) JP2006522116A (es)
CN (1) CN1535692A (es)
AR (1) AR043968A1 (es)
AU (1) AU2004226520A1 (es)
CA (1) CA2521052A1 (es)
CL (1) CL2004000722A1 (es)
MX (1) MXPA05010402A (es)
SE (1) SE0300971D0 (es)
WO (1) WO2004087212A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335181B2 (en) * 2000-12-26 2008-02-26 Pulmonox Technologies Corporation Nitric oxide decontamination of the upper respiratory tract
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
AU2004255268B2 (en) 2003-07-09 2010-04-01 Loma Linda University Use of nitrite salts for the treatment of cardiovascular conditions
JP2007534361A (ja) * 2003-12-15 2007-11-29 ニトリカーレ・ハンデルスボラーグ 治療薬を投与する装置および方法
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
CA2606565C (en) 2005-05-27 2016-05-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CN1990045B (zh) * 2005-12-30 2010-12-22 北京尼奥克斯生物科技有限公司 一种新型高效烧烫伤类贴剂及其制备方法
EP2209472A1 (en) * 2007-10-12 2010-07-28 The University of North Carolina at Chapel Hill Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
CA2710349A1 (en) * 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
BR112012008508A2 (pt) * 2009-10-13 2017-06-13 Novan Inc revestimento de sol-gel, substrato, método para produzir um revestimento de sol-gel
US20120107423A1 (en) * 2010-11-01 2012-05-03 Ino Therapeutics Llc Methods of Using Inhaled Nitric Oxide Gas for Treatment of Acute Respiratory Distress Syndrome
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012093383A1 (en) * 2011-01-04 2012-07-12 Radikal Therapeutics Inc. Compositions and methods for treatment of sepsis and related conditions
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
DK3421042T3 (da) * 2012-03-07 2024-07-22 Beyond Air Ltd Indånding af nitrogenoxid til behandling af luftvejssygdomme
EP3020438A1 (en) * 2014-11-13 2016-05-18 Linde AG Device for ventilating a patient and method for operating a device for ventilating a patient
WO2017130066A1 (en) * 2016-01-27 2017-08-03 Advanced Inhalation Therapies (Ait) Ltd. Methods of treatment of respiratory tract infections and cystic fibrosis
AU2017223689B2 (en) * 2016-02-25 2021-05-20 The Regents Of The University Of Michigan Nitric oxide generating formulations and kits
EP3444615B1 (en) * 2017-08-15 2021-09-08 Freiberg Instruments GmbH Methods and compositions for diagnostic evaluation and therapeutic correction of the no-haem signalling pathway(s) in animals and humans

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10299002I1 (de) * 1990-12-05 2012-07-05 Gen Hospital Corp Verwendung von No zur Behandlung oder Praevention der Bronchokonstriktion
US5814666A (en) * 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
DE4420523A1 (de) * 1994-06-13 1995-12-14 Cassella Ag Verwendung von NO-freisetzenden Verbindungen zur Behandlung und Vorbeugung von systemischen Entzündungssyndromen
WO1996002268A1 (en) * 1994-07-15 1996-02-01 Brigham And Women's Hospital Inhibition of virus by nitric oxide
WO1996031217A1 (en) * 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
IT1282686B1 (it) * 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5837698A (en) * 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
US5985862A (en) * 1996-05-02 1999-11-16 G.D. Searle & Co. Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs
US5985562A (en) * 1997-06-03 1999-11-16 Schering Aktiengesellschaft Method of detecting thrombotic disease risk associated with plasma carboxypeptidase B polymorphisms
JP2001509481A (ja) * 1997-07-11 2001-07-24 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 一酸化窒素はライノウイルス感染症を抑制する
US6656452B1 (en) * 1997-10-21 2003-12-02 The General Hospital Corporation Use of inhaled NO as anti-inflammatory agent
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
FR2812545B1 (fr) * 2000-08-03 2003-03-28 Air Liquide Sante Int Aerosol medicamenteux inhalable dans le traitement ou la prevention de la douceur
GB0022084D0 (en) * 2000-09-08 2000-10-25 Univ Aberdeen Treatment of multiply antibiotic-resistant organisms

Also Published As

Publication number Publication date
US20050069595A1 (en) 2005-03-31
CA2521052A1 (en) 2004-10-14
AU2004226520A1 (en) 2004-10-14
CN1535692A (zh) 2004-10-13
WO2004087212A3 (en) 2004-12-16
US20080089956A1 (en) 2008-04-17
MXPA05010402A (es) 2005-11-04
EP1608405A2 (en) 2005-12-28
JP2006522116A (ja) 2006-09-28
SE0300971D0 (sv) 2003-04-03
WO2004087212A2 (en) 2004-10-14
CL2004000722A1 (es) 2005-01-14

Similar Documents

Publication Publication Date Title
AR043968A1 (es) Oxido nitrico en el tratamiento de inflamacion
AR090143A2 (es) Composicion farmaceutica para inhibir el crecimiento de celulas anormales
CL2008002407A1 (es) Forma de dosificacion oral que comprende al menos un agente activo de nicotina, al menos un material bioadhesivo capaz de formar un enlace de hidrogeno con el agente activo de nicotina, y al menos un agente de impacto sensorial que se libere rapidamente; y su uso para proporcionar alivio rapido de las ansias de nicotina (div. sol. 1825-04).
CL2009000816A1 (es) Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras.
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
MX2019010171A (es) Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
NZ624059A (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
ES2733238T1 (es) Tratamiento de linfoma no Hodkings de grados intermedio y alto con anticuerpo anti CD20
UY28438A1 (es) Composicion de un antagonista de vegf y de un agente antiproliferativo
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
ECSP056078A (es) Composición de insulina inyectable de acción prolongada y métodos de fabricación y uso del mismo
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
AR030741A1 (es) Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
UY39468A (es) Materiales y métodos biosintéticos para el biotransporte multidireccional
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
UY27727A1 (es) Nueva composicion farmacéutica-
CO6280488A2 (es) Combinacion farmaceutica
SE0402221D0 (sv) Treatment of insufficient perfusion
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos

Legal Events

Date Code Title Description
FB Suspension of granting procedure